Stream 1 - Speaker Bios
Optimizing Cell Culture Technology
August 3-4, 2015
Woo Suk Ahn, Ph.D., Postdoctoral Associate, Chemical Engineering, Massachusetts Institute of Technology
Woo Suk Ahn is a Post Doc in Chemical Engineering at MIT. He is studying on tumor metabolism in Gregory Stephanopoulos group at MIT (2012 - present). Ahn earned his Ph.D. degree in Chemical Engineering at University of Delaware (2008 – 2012). His topic is on developing metabolic flux analysis methodology using isotopic-tracers and mass spectrometry. Ahn worked at LG Life Sciences in R&D Biotech Group (2000– 2008), where he developed culture processes for the production of therapeutic proteins.
Christian Bender, Ph.D., Computational Biologist, Global Drug Discovery, Global Biologics, Bayer HealthCare
After my studies in bioinformatics I joined the German Cancer Research Center, Heidelberg for my PhD in Biostatistics, dealing mainly with high throughput protein and gene expression data. I moved on to the TRON gGmbH of the University Medicine Mainz, Germany, where I worked on the identification of novel immune therapeutic target candidates for oncological indications. I joined Bayer Pharmaceuticals recently, where I work on data management and interpretation for Global Biologics Research.
Payal Biswas, Ph.D., Scientist, Upstream Process Development, Vaccine Production Program, Vaccine Research Center/NIAID/NIH
I have graduated from the University of California, Riverside and have moved to Maryland since then, and I currently work at the Vaccine Production Program which is a part of the Vaccine Research Center of NIAID. Being part of the vaccine development group, I have worked on several interesting and novel human vaccines. It gives me a great sense of satisfaction in knowing that the work we conduct will improve the health of millions of people in the United States and around the world.
Martin Heitmann, Ph.D., Senior Scientist, Cell Culture Technology, Novo Nordisk A/S
Martin Heitmann is senior scientist in the department Cell Culture Technology at Novo Nordisk A/S. The three main focus areas in the department are cell line evaluation, production of the first protein for non-clinical testing in animal models to obtain proof of concept and early process development for production of protein in mammalian cells. Since joining Novo Nordisk in 2011 Martin has focused on the development of scale-down tools for perfusion cultures as well as integrating perfusion cultivations and continuous purification for the production of complex proteins. Furthermore, Martin has previous experience in metabolome analysis of mammalian cells as well as downstream processing.
Gregory Hiller, Ph.D., Associate Research Fellow, Culture Process Development, BioProcess R&D, Pfizer, Inc.
Gregory Hiller is a group leader in Culture Process Development within Bioprocess Research and Development, Pfizer, in Andover, MA. Greg joined the group in Andover in 2003 after gaining a variety of experiences working for 10 years in the start-up biotech company, BioTransplant, just north of Boston. Greg is a chemical/biochemical engineer by training, an alumnus of the University of Cincinnati (B.S.) and University of California at Berkeley (PhD).
Wai Lam W. Ling, Ph.D., Process Development & Engineering, Biologics BioProcess Development, Merck Research Labs
Wai Lam Ling oversees upstream process development activities for early and late stage therapeutic protein development programs at Merck since 2009. Her scientific responsibilities include clonal selection, medium development, cell line characterization, and cellular profiling. Prior to Merck, she was the cell culture process development lead with Schering-Plough for 11 years responsible for the development of a number of monoclonal antibody programs, including Keytruda. Prior to Schering-Plough, she was a post-doctoral research fellow at Albert Einstein College of Medicine with research focus on post-translational modifications, protein trafficking and secretion in mammalian and yeast cells. Wai Lam received her Ph.D. in Pharmacology from the joint program of Rutgers University and University of Medicine & Dentistry of New Jersey, and B.S. in Biochemistry from UCLA.
Richard R. Meehan, Ph.D., Project Leader, Chromosomes and Gene Expresion, MRC Human Genetics Unit, IGMM, University of Edinburgh
Professor Richard R. Meehan is a genetics graduate of TCD (Dublin, Ireland) and has been studying DNA methylation dynamics for over 25 years. Research landmarks include the identification of methyl-CpG binding proteins, non-catalytic roles for the maintenance methyltransferase DNMT1 and the potential of 5-hydroxymethycytosine profiling as ‘biomarker’ of cellular state. He is currently a Professor at the MRC Human Genetics Unit in Edinburgh.
Jessica Mondia, Ph.D., Research Scientist, Biogen Idec, Inc.
Jessica Mondia received her PhD in physics from the University of Toronto in 2005. She held two post-doctoral positions: one in Germany at the Max Planck Research Group, Institute for Optics, Information and Photonics studying the optical properties of nanoparticles; and another in the Biomedical Engineering and Physics Departments at Tufts University studying silk-based biophotonic devices and laser ablation of biomaterials. In 2012 Jessica joined Biogen Idec, where she has been developing analytical methods to characterize cell culture raw material and working on biopharmaceutical forensic investigations.
Arnaud Périlleux, Assistant Project Manager, Biotech Process Science, Merck Serono SA
After getting his engineering degree in Biotechnology (ENSTBB, Bordeaux, France), Arnaud joined the Merck Serono group in 2008 as a Scientist in the cell culture department and is now project manager for process development activities.
Arnaud has worked on the development of a fed-batch platform for recombinant mammalian cell lines. He participated in the optimization of cell culture conditions through the different scales, from micro scale up to 15KL bioreactor. He led the development of cell culture media and feeds, and of predictive methods for high-throughput cell line selection and process development.
As a scientific expert in upstream, he was also involved in early process adaptation for preclinical and phase I clinical studies. He participated in the implementation of the state-of-the-art technologies, aiming to rationalize process knowledge, such as scientific data management, multivariate analysis, and design of experiments.
As project manager, he is coordinating technical teams from upstream, downstream and analytical groups for efficient process development of new biopharmaceutical products and biosimilars, providing objectives, organization, and also scientific expertise.
Daryl Powers, Ph.D., Senior Scientist, Early Cell Culture Development, Sanofi Global Biotherapeutics
Daryl is a scientist in the early upstream process development organization within Sanofi Global Biotherapeutics. He is responsible for developing upstream processes for phase I/II clinical production of recombinant proteins within the Sanofi portfolio. He is also working on projects to improve the Sanofi early upstream process development platform. Prior to his position in Sanofi, Daryl has held positions as a Scientist at Millipore working on upstream bioprocess product development and as a Scientist at Percivia working on media and fed-batch process development for protein production using PerC6 cells. Daryl holds BS and PhD degrees in chemical engineering.
Christopher Rives, Ph.D., Senior Upstream Development Engineer, BioProcess Development, Shire plc
Chris Rives is a Senior Upstream Development Engineer in the BioProcess Development Group at Shire. He received a Ph.D. in Chemical Engineering from Northwestern University in 2008, and has 6+ years of experience in cell culture process development that includes early and late-stage process development, tech transfer/scale-up, and manufacturing support.
Kristin Valente, Ph.D., Associate Principal Scientist, Merck
Kristin Valente is currently an Associate Principal Scientist within Global Vaccines & Biologics Commercialization at Merck. She has over 5 years of industrial experience in early-stage process development and clinical supply manufacture. She received her doctorate from University of Delaware in 2014. Her doctoral research focused on optimizing & applying proteomic methods to study host cell proteins expressed by CHO cells. In her current role, she leads late-stage downstream process development and commercial support of viral vaccine products.
Wenqi Xie, Associate Scientist III, Cell Culture Development, Biogen, Inc.
Wenqi is an associate scientist in the Cell Culture Development team at Biogen. Her work focuses on developing small-scale mammalian cell culture processes for clinical programs and enhancing internal capabilities through platform innovation, including increasing understanding and maximizing usability of capability-enhancing technologies. Prior to joining Biogen, Wenqi was at Percivia where she worked on process development for the PER.C6 cell line platform and their biosimilar programs. Wenqi holds a B.S. degree from Sun Yat-sen University in China and M.S. degree from Northeastern University, both in Biotechnology.
Joanne T. Beck, Ph.D., Senior Vice President, Pharmaceutical Development, Shire Pharmaceuticals
Dr. Beck is currently Senior Vice President of Pharmaceutical Development at Shire. Her function is responsible for pharmaceutical development for Shire’s pipeline and commercial pharmaceutical and biopharmaceutical products.
Dr. Beck has close to 25 years of experience in Product Development and Operations leadership. She holds a BA in Chemistry from Lewis and Clark College, a Ph.D. in Biochemistry and Molecular Biology from University of Oregon Medical School, and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco. From 1992-2002 she held roles of increasing responsibility in Process Development, first at Genentech and then at Amgen and in 2002 she joined a start-up, Altus Pharmaceuticals, as Director of Operations. From 2004 to 2012 she held a variety of senior leadership roles at Abbott, including positions as head of Program Management and Plant Manager at the Abbott Bioresearch Center, site head of Abbott Vascular Instruments Deutschland GmbH, and head of Global Operational Excellence group for Abbott’s Global Pharmaceutical Operations. She joined Shire in 2012 as VP of Process Development and Manufacturing Science.
Bioproduction: Scale, Bioreactors & Disposables
August 5-6, 2015
Chad Atwell, MS, Associate Director, Manufacturing Science and Technology, Genzyme Corporation
Chad Atwell has over 17 years of industry experience in biotechnology manufacturing and process development including the launch of three commercial antibody products for Bristol-Myers Squibb and has a M.S. degree in Biotechnology from the Johns Hopkins University. He has managed groups in manufacturing, process development, and manufacturing technical services (MTS). Mr. Atwell joined Genzyme’s MTS organization in 2011, and is now the Associate Director of the Manufacturing Science Laboratory.
Simona Capone, Project Assistant, Chemical Engineering, Vienna University of Technology
I was born in Avellino, South of Italy on May 25th, 1986. In 2001, I moved to Milan where I did high school and university studies. Since 2010 I have been in Vienna, Austria, where I am currently finishing my PhD.
My academic training and research experiences have provided me with a very good background in multiple biological disciplines including molecular biology, microbiology, biochemistry, genetics, bioprocess engineering and downstream processing. Furthermore during my graduated studies I have repeatedly worked with Pichia pastoris as host for heterologous protein expression acquiring good competences regarding the physiology of this organism.
During my master thesis, under supervision of Dr. Brigitte Gasser, I worked on a project for characterizing secretion of recombinant protein in the yeast Pichia pastoris. In this period, I have developed a critical approach for finding solutions to scientific problems and developed good team working skills.
During my Ph.D. studies, which are still ongoing, I had the great pleasure to work on the research project “Glycoengineered horseradish peroxidase for targeted cancer treatment” under supervision of Dr. Oliver Spadiut. The work on this project gave me the chance of significantly improving my scientific knowledge. Additionally, during these 3 years of Ph.D. studies, I have strongly improved my communication, organization and team working skills, thanks also to the opportunity of attending 3 international conferences as a speaker, and from working in a very stimulating team together with graduate and under-graduate students.
Stephen Hsu, MSc., Senior Research Associate II, Gilead Sciences
Stephen Hsu is a scientist in the upstream process development group of Gilead Sciences’s Bioprocess development Division located in Oceanside, CA. He received B.S./M.S. degrees in Cell and Molecular Biology from UC San Diego in 2008 and an M.B.S. degree in Bioprocessing from the Keck Graduate Institute, Claremont in 2012. Stephen currently supports process development, process characterization, as well as internal and external technology transfer molecules for the Gilead biologics pipeline.
David Kolwyck, MBA, Director, Manufacturing Sciences, Raw Materials, Biogen Idec, Inc.
I’ve spent 10 years on the supplier side of the industry focused on chemicals and media for biopharma production prior to moving to the manufacturing side. I was the upstream raw material network lead at Amgen prior to becoming the Global Process Owner for Raw Materials at Biogen IDEC within the Manufacturing Science organization. My current responsibilities include developing and executing technical strategies for supply chain risk mitigation, creating technical development programs with strategic suppliers and applying process analytics to minimize variability in the manufacturing network due to raw materials. My other interests include outdoor activities such as road biking and fishing.
Michelle LaFond, Director, Bioreactor Scale-Up and Development, Regeneron Pharmaceuticals
Michelle joined Regeneron in 1999 as a member of the Bioreactor Scale-Up & Development group within Preclinical Manufacturing and Process Development. She has focused her career on scale-up of CHO-expressed products (recombinant proteins, monoclonal antibodies) to pilot scale for preclinical studies, robustness testing for second generation processes, and is skilled in troubleshooting issues that arise during process scale-up. Michelle has been involved in the development and transfer of processes to Regeneron Manufacturing to produce material for early and late phase human clinical trials and has produced preclinical material for toxicology studies for over 25 programs. Michelle was a lead team member responsible for the specifications and design of Regeneron’s state of the art pilot bioreactor suite constructed in 2009. Michelle’s awards include being named one of Westchester County’s 40 Under 40 Rising Stars by the Business Council of Westchester in June 2010 and 2015 Rising Star for the Healthcare Businesswomen’s Association. Michelle graduated from University of Connecticut in December 1998 with a Bachelor of Science in Chemical Engineering
Weimin Lin, M.D., Process Development Scientist, Biogen Idec, Inc.
Dr. Weimin Lin is a process development scientist in the Department of Technical Development at Biogen Idec. She received her M.D. at the Peking University in China and worked in the Department of Cardiology at Beijing An-Zhen Hospital for three years. For the past six years at Biogen Idec, she has leaded process development of multiple clinical and commercial products.
Hunter Malanson, Scientist I, Upstream Development, Alexion Pharmaceuticals
A Pharmaceutical Industry Veteran with 15 years of collective process development experience and expertise in both Upstream and Downstream Processing with knowledge of pre-clinical, early, mid, and late-stage biological processes.
Matthew Manahan, MSc., Scientist, Bioprocess Development, Merck & Co., Inc.
Eighteen years in Bioprocess Development with Schering Plough and now Merck. The majority of my career has been spent in development and understanding of monoclonal antibody processes and most recently working with E. coli expression systems for various internal programs.
Peter F. Moesta, Ph.D., Senior Vice President, Biologics Development & Operations, Bristol Myers Squibb Co.
Peter Moesta, Ph.D. is the Senior Vice President, Biologics Development and Operations for Bristol-Myers Squib (BMS). Joining BMS in early 2011, Peter leads the broad based technical activities between R&D and Manufacturing organizations to support the successful clinical development, registration, manufacturing and commercialization of biologics products.
Peter has extensive experience in biologics manufacturing, including process development, clinical and commercial manufacturing and supply chain across global operations. Before joining Bristol-Myers Squibb, he served as Division Vice President, Biologics Manufacturing for Abbott Laboratories where he guided the manufacturing process and led the CMC effort to obtain approval for Humira. He also led the design, start-up and registration of the company’s large scale biologics manufacturing plant in Puerto Rico.
Earlier in his career Peter worked for BASF for 17 years, both in Germany and the US. He held positions of increasing responsibility before becoming Vice President, Process Development and Operations for BASF Bioresearch Corporation in Worcester MA. While at BASF, he planned and executed the construction of a combined research and biologics production facility for BASF, then built a successful multi-disciplinary team to develop and manufacture therapeutic proteins at the facility.
Peter earned his Master’s degree in Chemistry and a PhD in Biochemistry from the University of Freiburg in Germany. He completed post-doctoral fellowships at the University of Freiburg and at UCLA.
Nirel Rillera, Research Associate II, BioMarin Pharmaceuticals, Inc.
Nirel was born and raised in Southern California, where she spent most of her life soaking up the sun all year round. She then made the bold decision to brave the colder weather and travel further up north where she attend University of California, Davis. After graduating from UC Davis with a Bachelor of Science in Biochemical Engineering, Nirel went on to work for BioMarin Pharmaceutical Inc., where she has been working for over 2 and a half years.
Stefan Schmidt, Ph.D., MBA, Vice President, Process Science & Production, Rentschler Biotechnologie GmbH
Dr. Stefan R. Schmidt MBA, currently serves as Vice President at Rentschler Biotechnology. Previously he held the CSO position at ERA Biotech in Barcelona, directing the company’s R&D efforts focusing on fusion peptides. Prior to that he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences as Associate Director. In the last 10 years he worked intensively with fusion proteins, just recently publishing the first comprehensive book on that topic.
Jose R. Vallejos, Ph.D., Scientist I, Manufacturing Sciences and Technology (MS&T), AstraZeneca/Medimmune
In 2011, Dr. Vallejos earned his Doctorate Degree in Chemical Engineering from the University of Maryland at Baltimore County (UMBC) under the supervision of Professor Dr. Antonio Moreira and Professor Dr. Govind Rao at the Center of Advanced Sensor Technology (CAST). Dr. Vallejos is a Fulbright-awarded scientist who has contributed significantly to reduce the process information gap in the Biotech Process Development field. In the past years, he has worked in collaboration with national and international leading scientists in the optical sensor and Process Scouting Devices (PSDs) characterization fields. Dr. Vallejos' research work in Mixing and Mass Transfer characterization of multi/single-use Process Scouting Devices (PSDs) using non-invasive optical sensors has been published in prestigious peer-reviewed scientific journals and in the Reference Book Comprehensive Biotechnology, 2nd Edition (Published by Elsevier). Additionally, he has presented his research work in Scientific National and International Meetings and Conferences.
Jonathan Wang, Process Engineer Associate, Late Stage Cell Culture Development, Sanofi
Jonathan Wang graduated from Northeastern University with a B.Sc. in Biology and is a nationally registered EMT. Jon is currently a Process Engineer Associate in Genzyme’s Late Stage Cell Culture Development where he works on perfusion processes for mammalian cell culture.
Optimizing Cell Line Development
August 6-7, 2015
Christina Alves, Ph.D., Scientist, Cell Culture Development, Biogen Idec, Inc.
After graduating with a BS in Chemical Engineering from Northeastern University in Boston, I spent several years in cell culture and fermentation development at Chiron Corp in Emeryville, CA. After developing processes and recovery steps for several different cell types, including CHO, yeast, and E. Coli, I left to pursue a PhD in Biomolecular Engineering at Johns Hopkins University in Baltimore, MD, where I studied host cell interactions in cancer biology. Since 2009, I have been part of the cell line technology group at Biogen Idec in Cambridge, MA optimizing high throughput cell line screening and developing improved systems for mammalian cell expression.
Alan Dickson, Ph.D., Professor and Director, Centre of Excellence in Biopharmaceuticals (COEBP), University of Manchester
Alan Dickson is a molecular cell biologist who has worked as a collaborator with industry in the area of cell line development and expression of biopharmaceuticals for more than 20 years. Alan is Chair of Biotechnology and Director of the Centre of Excellence in Biopharmaceuticals (http://www.coebp.ls.manchester.ac.uk) at the University of Manchester and holds several positions of sector responsibility (Co-Director of BioProNET http://www.biopronetuk.org, funded by BBSRC/EPSRC, member of the Steering Committee of the Bioprocess Research Industry Club, Scientific Committee member for BioProcessUK, member of the Executive Committee of the European Society of Animal Cell Technology).
A Scot, Alan obtained his BSc and PhD from the University of Edinburgh before undertaking his research fellowship at the University of Kent. In Manchester, Alan has had several senior administrative positions in the Faculty of Life Sciences, acting as Dean for Graduate Education and Dean for Communications.
Yves Durocher, Ph.D., Research Officer, Human Health Therapeutics Portfolio, Biologics & Biomanufacturing Program, National Research Council Canada
Yves Durocher is a Research Officer at the National Research Council of Canada since 1995. He obtained his PhD in Biochemistry at the Universite de Montreal in 1993. Yves manages a team of 21 people involved in protein expression and cell line development for internal projects and external clients. His research activities have been focused on the development the of large-scale transient gene expression (LSTGE) platforms using HEK293 and CHO cells for protein production. More recently, he has been focusing on developing and engineering a stable CHO cell line platform for recombinant protein manufacturing. Yves is also an assistant professor at the Department of Biochemistry at the University of Montreal.
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Lab for Cancer Research
Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on providing production of Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on Ras biology including structural biology, biophysics, and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his B.A. in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.
Dieter Gruenert, Ph.D., Professor, Otolaryngology-Head and Neck Surgery, University of California, San Francisco
Dr Dieter Gruenert is a Professor in the Department of Otolaryngology-Head and Neck Surgery and is a member of the Eli Edythe Broad Center for Regenerative Medicine and Stem Cell Research, the Institute for Human Genetics, the Helen Diller Family Comprehensive Cancer Center, and the Cardiovascular Research Institute at UCSF as well as an Adjunct Professor in the Department of Pediatrics at the University of Vermont. He received his Ph.D. in Biophysics from UC Berkeley in 1982 and was postdoctoral fellow (1982-1984) in the Department of Carcinogenesis at the Swiss Institute for Experimental Cancer Research in Lausanne, Switzerland. He originally joined the faculty at UCSF in 1986 where he developed many of the human cystic fibrosis (CF) and non-CF airway epithelial cell lines used in CF and airway disease research throughout the world. He was the Co-Director of the Gene Therapy Core Center at UCSF from 1992-1999, and served as a Professor of Medicine and Director of the Division of Human Molecular Genetics at the University of Vermont from 2000-2003. From 2003-2010 he was a Senior Scientist and Head of the Stem Cell Research Program at the California Pacific Medical Center before returning to UCSF. His present research continues to focus on human cell and molecular biology as they relate to the development of gene and cell-based therapies for inherited diseases like cystic fibrosis and sickle cell anemia. Over the years, his work has led to development of novel diagnostic and oligo/polynucleotide-based therapeutic strategies, nucleic acid delivery approaches, and to the development of numerous immortalized and therapeutic pluripotent human cell systems that are being used globally for the last 25 years to study not only CF, but other airway diseases and cancer. He has > 150 publications, holds 5 patents, reviews grants for numerous national and international agencies, is on the Editorial Boards of a number prestigious scientific journals and is a Senior Editor of Nucleic Acid Therapeutics and the Deputy Editor of Molecular Therapy Nucleic Acids. He has served on numerous ASGCT committees including the Non-viral, the Oligonucleotide and RNAi Therapeutics, the Respiratory Tract Gene & Cell Therapy, and the Ethics Committees of which he also served as Chair (2008-2011). He is currently a member of the National Agency for Evaluation of Candidates of Professor and Associate Professor for the Italian Ministry for Education, Universities and Research. He was awarded a European Respiratory Society Visiting Professorship at the Necker Hospital in Paris and holds Visiting Professorship at Tor Vergata University in Rome.
Donald Jarvis, Ph.D., Professor, Molecular Biology, University of Wyoming
Ph.D. (1986) in Virology at Baylor College of Medicine. Postdoctoral (1987-1989) Texas A&M University, began research focused on glycoprotein biosynthesis and processing in the baculovirus system with Max Summers. Assistant Professor (1989 - 1995) Texas A&M University, same research topic. Associate Professor (1995 - 1997) Texas A&M University, same research topic. Associate Professor (1998 - 2000) Univ of Wyoming, same research topic. Professor (2000 -present) Univ of Wyoming, same research topic. Preseident (2011 - present) GlycoBac, LLC, spun out to refine and commercialize improved baculovirus-insect cell systems for recombinant glycoprotein production.
Claus Kristensen, Ph.D., Associate Professor, Copenhagen Center for Glycomics (CCG), University of Copenhagen
- Assistant professor at Copenhagen Center for Glycomics, University of Copenhagen
- Works on glycoengineering of mammalian cells
- Former Director for Mammalian Cell Technologies at Novo Nordisk
- Extensive experience with developing mammalian production cell lines for antibodies and coagulation factors
- Development of 10 mammalian production cell lines supporting clinical trials, including one marketed product (Novoeight)
Nathan Lewis, Ph.D., Assistant Professor, Systems Biology Research Group, University of California, San Diego
Dr. Lewis is an Assistant Professor in the Department of Pediatrics at the University of California, San Diego, where he is a member of the Division of Pediatric Pharmacology and Drug Discovery. In conjunction with the Novo Nordisk Foundation Center for Biosustainability, his research group focuses on the construction of systems biology models of metabolism, glycosylation and protein secretion in mammalian systems. He also helped lead previous efforts to sequence the CHO-K1 and Chinese hamster genome sequences, and is an active participant in community efforts to refine the publically available genomic resources for CHO cell engineering. Previously he was a postdoctoral fellow at Harvard Medical School where he worked on stem cell differentiation and genome editing technologies, and he received his Ph.D. in Bioengineering at UC San Diego where he developed novel approaches for omic-data analysis using systems biology modeling techniques.
Pamela Pegman, Ph.D., Senior Principal Scientist, Cell Line Development, Pfizer, Inc.
Pam has over 10 years of combined experience in the areas of protein expression, cell line development and the development of monoclonal antibody and recombinant biotherapeutic protein expression platforms in mammalian and microbial systems. Pam joined Pfizer in 2013 as group leader in the cell line development department, which is part of the Biotherapeutics R&D organization. Prior to her current position, Pam was an Associate Director at Eleven Biotherapeutics in Cambridge MA, where she developed expression systems to support both discovery and development candidates. Pam has also spent over 5 years at Amgen where she managed the protein sciences group in Cambridge MA. Prior to coming to the US, Pam worked in the cell line development group at GSK in the UK, having received her Ph.D. from Dublin City University in 2003.
Shashi Prajapati, Ph.D., Senior Scientist, High-Throughput Analytical Group, Cell Culture Development, Biogen Idec, Inc.
Shashi Prajapati is working in Biogen as Sr. Scientist. Her group works in developing high-throughput product quantitation and product quality analytical assays to support the cell line development and cell culture process development. Prior to Biogen, Shashi worked in Bristol Myers Squibb where her groups was supported the high-throughput analytical assays for upstream and downstream process developments activities. Before BMS, Shashi worked in Eli Lilly, Indianapolis in Cancer drug discovery department and worked on the NF-KappaB pathway. Shashi has Ph.D in Biochemistry from Central Drug Institute, India in Protein Folding area and she did her postdoc in UT Southwestern Medical Center Dallas, TX in NF-KappaB pathway.
Rainer Stahn, Ph.D., Head, Bioprocess Development, Glycotope GmbH
Head of Bioprocess Development. Joined Glycotope in 2007. Ph.D. in Bioprocess Engineering from TU Berlin Study of Biotechnology in Berlin and Stockholm.
Erwin Swennen, Ph.D., Manager, Cell Line and Process Analytics, Bacterial Drug Substance Development, Novartis Vaccines
Dr. Erwin Swennen currently leads the unit Cell line and Process Analytics of the Novartis Vaccines Technical Development organization. After completion of his scientific education [Bachelor of Applied Science in Chemistry from the Catholic University of Leuven (KUL) (1993), Master degree in Biological Sciences (1998) and a PhD in Industrial Fermentation and Applied Bio-catalysis (2001) from the University of Bologna], he joined (October 2001) the Chiron and successively Novartis Research organization to start up and lead the Laboratory Fermentation Development. For 10 years in this role, he contributed and offered constant support to the research projects through activities going from cell line engineering and development of antigen production processes to tuning of process analytical tools, isotope labeling and unnatural amino acid incorporation. He joined the Novartis Vaccines Technical Development organization in Feb. 2012 to start up Microbial Cell Line Development in Siena. In April 2014, the unit Cell line and Process Analytics was created to respond to the need for more appropriate early process analytical tools also in the US and DS processes.
Wen Wang, Ph.D., Postdoctoral Associate, Chemical Engineering, Massachusetts Institute of Technology (MIT)
Wen Wang is currently working as a Postdoctoral Associate in Professor Daniel I. C. Wang’s lab in the Department of Chemical Engineering at Massachusetts Institute of Technology (MIT). She is also an adjunct Postdoc in Professor Hiroshi Ishii’s lab at the MIT Media Lab. Her research interests include bioprocessing, biocatalysis and biofabrication across different industries from pharmaceutical production to biodesign.